Full Press Release Details
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE setmelanotide for Use in Patients with Bardet Biedl Syndrome.
RYTM
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE setmelanotide for Use in Patients with Bardet Biedl Syndrome
Key Takeaway: Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE setmelanotide for Use in Patients with Bardet Biedl Syndrome